Insight Molecular Diagnostics Inc. (IMDX) Earnings History
Annual and quarterly earnings data from 2013 to 2024
Loading earnings history...
IMDX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IMDX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 39.3% | -3245.1% | -3225.0% |
| 2023 | 27.5% | -1672.4% | -1848.4% |
| 2022 | -1.9% | -1878.6% | -7609.8% |
| 2021 | 64.6% | -2444.3% | -2916.2% |
| 2020 | -52.5% | -2443.3% | -2461.5% |
Download Data
Export IMDX earnings history in CSV or JSON format
Free sign-in required to download data
Insight Molecular Diagnostics Inc. (IMDX) Earnings Overview
As of May 8, 2026, Insight Molecular Diagnostics Inc. (IMDX) reported trailing twelve-month net income of -$61M, reflecting -24.3% year-over-year growth. The company earned $-1.90 per diluted share over the past four quarters, with a net profit margin of -3225.0%.
Looking at the long-term picture, IMDX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2013.
Insight Molecular Diagnostics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NTRA (-$208M net income, -9.0% margin), EXAS (-$208M net income, -6.4% margin), CDNA (-$8M net income, -5.6% margin), IMDX has room to improve margins relative to the peer group. Compare IMDX vs NTRA →
IMDX Earnings vs Peers
Earnings metrics vs comparable public companies
IMDX Historical Earnings Data (2013–2024)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$61M | -118.4% | -$61M | $-4.66 | -3225.0% | -3245.1% |
| 2023 | -$28M | +61.9% | -$25M | $-3.75 | -1848.4% | -1672.4% |
| 2022 | -$73M | -13.7% | -$18M | $-20.00 | -7609.8% | -1878.6% |
| 2021 | -$64M | -114.1% | -$54M | $-14.40 | -2916.2% | -2444.3% |
| 2020 | -$30M | -34.0% | -$30M | $-9.14 | -2461.5% | -2443.3% |
| 2019 | -$22M | -41.7% | -$22M | $-8.71 | - | - |
| 2018 | -$16M | +18.7% | -$15M | $-8.32 | - | - |
| 2017 | -$19M | -73.5% | -$19M | $-12.83 | - | - |
| 2016 | -$11M | -27.9% | -$11M | $-8.42 | - | - |
| 2015 | -$9M | -75.2% | -$9M | $-8.32 | - | - |
See IMDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIMDX — Frequently Asked Questions
Quick answers to the most common questions about buying IMDX stock.
Is IMDX growing earnings?
IMDX EPS fell to $-1.90, with earnings declining -24.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-61M.
What are IMDX's profit margins?
Insight Molecular Diagnostics Inc. net margin is -3225.0%, with operating margin at -3245.1%. Below-average margins reflect competitive or cost pressures.
How consistent are IMDX's earnings?
IMDX earnings data spans 2013-2024. The declining earnings trend is -24.3% YoY. Historical data enables comparison across business cycles.